Laura Prendergast
Stock Analyst at Stifel Nicolaus
(4.85)
# 364
Out of 4,491 analysts
77
Total ratings
71.9%
Success rate
55.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintained: Buy | $215 | $188.32 | +14.17% | 18 | Jun 29, 2026 | |
| COGT Cogent Biosciences | Maintained: Buy | $45 | $39.97 | +12.58% | 9 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiated Coverage: Buy | $14 | $10.47 | +33.78% | 1 | Jun 12, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $135 → $124 | $123.83 | +0.14% | 7 | Jun 10, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $12 | $6.05 | +98.35% | 6 | Jun 1, 2026 | |
| ERAS Erasca | Maintained: Buy | $30 | $18.42 | +62.87% | 11 | Jun 1, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $40 | $30.19 | +32.49% | 9 | May 25, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $8 | $1.90 | +321.05% | 6 | May 22, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $23 | $9.02 | +154.99% | 4 | May 13, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $48 | $11.94 | +302.01% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $13.50 | -11.14% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $9.28 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $3.51 | n/a | 1 | Aug 14, 2024 |
Revolution Medicines
Jun 29, 2026
Maintained: Buy
Price Target: $215
Current: $188.32
Upside: +14.17%
Cogent Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $45
Current: $39.97
Upside: +12.58%
ORIC Pharmaceuticals
Jun 12, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $10.47
Upside: +33.78%
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $135 → $124
Current: $123.83
Upside: +0.14%
Foghorn Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $12
Current: $6.05
Upside: +98.35%
Erasca
Jun 1, 2026
Maintained: Buy
Price Target: $30
Current: $18.42
Upside: +62.87%
Tango Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $40
Current: $30.19
Upside: +32.49%
Black Diamond Therapeutics
May 22, 2026
Maintained: Buy
Price Target: $8
Current: $1.90
Upside: +321.05%
BridgeBio Oncology Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $23
Current: $9.02
Upside: +154.99%
Olema Pharmaceuticals
Feb 11, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $11.94
Upside: +302.01%
Jul 29, 2025
Maintained: Buy
Price Target: $12
Current: $13.50
Upside: -11.14%
Feb 13, 2025
Maintained: Buy
Price Target: $4
Current: $9.28
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $3.51
Upside: n/a